Please provide your email address to receive an email when new articles are posted on . Most patients with non-muscle-invasive bladder cancer who received TAR-200 with gemcitabine achieved complete ...
Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options. Non-muscle-invasive bladder cancer remains a ...
KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead ...
Provectus (PVCT) Biopharmaceuticals announced the start of a preclinical study of its lead investigational drug PV-10 in an orthotopic bladder cancer model. Results are expected in the first quarter ...
On busy days, you may not feel you have the time to sit on a toilet and wait for your bladder to empty, so you “power pee” — you bear down to expel urine faster. “Power peeing is a really common habit ...
(Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a comprehensive review of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback